Cancer Letters · 2018 · 92 citations · 34 references
MedicineOncologyPharmacologyCancer PharmacologyImmunotherapyMolecular OncologyAntitumor T Cell ResponsesApoptosis ResistanceCancer ImmunotherapyLung Cancer PharmacotherapyMyeloid-derived Suppressor CellsTumor Suppressor GenesIndoleamine 2, 3-Dioxygenase PathwayMyeloid-derived Suppressor Cell FunctionMyeloid-derived Suppressor Cell ModulationMyeloid-derived Suppressor Cell Signaling PathwaysMyeloid-derived Suppressor Cell Therapy ResistanceMyeloid-derived Suppressor Cell-mediated SuppressionProgrammed Death-ligand 1 Inhibition
34
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn et al. · New England Journal of Medicine · 2015 · 9.5K citations · Full text
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie R. Brahmer, Karen L. Reckamp, Lucio Crinò et al. · New England Journal of Medicine · 2015 · 8.6K citations · Full text
Pharmacy, Oncology, Pharmacotherapy +15
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh, Christina L. Harview, Jennifer H. Yearley et al. · Nature · 2014 · 6.6K citations · Full text
Life Sciences, Immunology, Pathology +14